Targeting the Transnitrosylation Cascade Provides a Novel Therapeutic Strategy for Alzheimer’s Disease  

作　　者：Yi Liu Gang Wu Xiji Shu Xiaochuan Wang 

机构地区：[1]Department of Pathophysiology,School of Basic Medicine,Key Laboratory of Education Ministry of China for Neurological Disorders,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China [2]Department of Pathology and Pathophysiology,School of Medicine,Jianghan University,Wuhan 430056,China [3]Co-innovation Center of Neuroregeneration,Nantong University,Nantong 226001,China

出　　处：《Neuroscience Bulletin》2021年第9期1373-1376,共4页神经科学通报（英文版）

基　　金：This research highlight article was supported by grants from the National Natural Science Foundation of China(92049107 and 31771114);Innovative Research Groups of the National Natural Science Foundation of China(81721005);the Ministry of Science and Technology of China(2016YFC1305800)。

摘　　要：As a major public health problem in modern society,Alzheimer’s disease(AD)is currently the most widely prevalent neurodegenerative disease,which will indubitably increase dramatically in the coming years,unless drugs that can prevent or cure the disease become available.Because AD is characterized histopathologically by extracellular deposition of amyloid beta(Aβ)surrounded by dystrophic neuritis forming senile plaques(SPs).

关 键 词：ALZHEIMER DRUGS AΒ 

分 类 号：R749.16[医药卫生—神经病学与精神病学]